

Grigory A Tsauro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7124421/publications.pdf>

Version: 2024-02-01

58
papers

1,607
citations

840119

11
h-index

344852

36
g-index

59
all docs

59
docs citations

59
times ranked

2925
citing authors

#	ARTICLE	IF	CITATIONS
1	The MLL recombinome of acute leukemias in 2017. <i>Leukemia</i> , 2018, 32, 273-284.	3.3	527
2	The MLL recombinome of acute leukemias in 2013. <i>Leukemia</i> , 2013, 27, 2165-2176.	3.3	393
3	New insights to the MLL recombinome of acute leukemias. <i>Leukemia</i> , 2009, 23, 1490-1499.	3.3	363
4	Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. <i>Blood Advances</i> , 2019, 3, 148-157.	2.5	48
5	Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions. <i>Leukemia</i> , 2019, 33, 2306-2340.	3.3	41
6	RUSSIAN-BELARUSIAN MULTICENTER GROUP STANDARD GUIDELINES FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA FLOW CYTOMETRIC DIAGNOSTICS. <i>Oncogematologiya</i> , 2018, 13, 73-82.	0.1	25
7	Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1331-1339.	1.2	24
8	Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4019.	1.8	18
9	Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 535-542.	1.2	15
10	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. <i>Leukemia</i> , 2020, 34, 3042-3046.	3.3	13
11	Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27354.	0.8	12
12	Contribution of All-Trans Retinoic Acid to Improved Early Relapse-Free Outcome in Infant Acute Lymphoblastic Leukemia Comparing to the Chemotherapy Alone.. <i>Blood</i> , 2007, 110, 2828-2828.	0.6	12
13	A Novel Three-Colour Fluorescence in Situ Hybridization Approach for the Detection of t(7;12)(q36;p13) in Acute Myeloid Leukaemia Reveals New Cryptic Three Way Translocation t(7;12;16). <i>Cancers</i> , 2013, 5, 281-295.	1.7	11
14	A new variant of KMT2A(MLL)-FLNA fusion transcript in acute myeloid leukemia with ins(X;11)(q28;q23q23). <i>Cancer Genetics</i> , 2015, 208, 148-151.	0.2	9
15	Blinatumomab following haematopoietic stem cell transplantation – a novel approach for the treatment of acute lymphoblastic leukaemia in infants. <i>British Journal of Haematology</i> , 2021, 194, 174-178.	1.2	8
16	Prognostic value of minimal residual disease measured by fusion gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol. <i>British Journal of Haematology</i> , 2021, 193, 1151-1156.	1.2	8
17	Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements. <i>British Journal of Haematology</i> , 2023, 201, 510-519.	1.2	8
18	Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2803-2811.	1.2	7

#	ARTICLE	IF	CITATIONS
19	IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. <i>Translational Oncology</i> , 2019, 12, 726-732.	1.7	7
20	Acute myeloid leukemia with t(10;11)(p11;q23.3): Results of Russian Pediatric AML registration study. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 287-292.	0.7	6
21	A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results. <i>Leukemia</i> , 2022, 36, 1382-1385.	3.3	6
22	Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia. <i>Molecular Biology</i> , 2016, 50, 852-859.	0.4	5
23	BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia. <i>Biomedicines</i> , 2021, 9, 924.	1.4	5
24	Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report. <i>Leukemia Research</i> , 2022, 112, 106758.	0.4	5
25	Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB). <i>Leukemia and Lymphoma</i> , 2019, 60, 426-432.	0.6	4
26	Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients. <i>BMC Medical Genomics</i> , 2019, 12, 37.	0.7	4
27	MLL genomic DNA Breakpoints In Infant Acute Leukemia. <i>Blood</i> , 2013, 122, 1350-1350.	0.6	3
28	Prognostic significance of various 11q23/KMT2A rearrangements in infants with acute lymphoblastic leukemia. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 27-39.	0.1	2
29	MLL-USP2: An Underestimated New Entity of MLL-Rearranged Leukemia Identified By NGS Analysis. <i>Blood</i> , 2018, 132, 3920-3920.	0.6	2
30	Molecular Remission in MLL/AF4-Positive Infant Leukemia Treated with the All Trans-Retinoic Acid Based MLL-Baby Protocol.. <i>Blood</i> , 2007, 110, 4254-4254.	0.6	2
31	Does ATRA Confirm to Play a Role in the Better Relapse Free Survival of Infants with Acute Lymphoblastic Leukemia?. <i>Blood</i> , 2011, 118, 1515-1515.	0.6	2
32	Application of Real-Time PCR for the Detection of BCR-ABL1-like Group in Pediatric Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2018, 132, 1376-1376.	0.6	2
33	BCR-ABL1-like pediatric acute lymphoblastic leukemia. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2019, 18, 112-126.	0.1	2
34	Immunophenotypic characterization of acute megakaryoblastic leukaemia in children. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2019, 18, 35-40.	0.1	2
35	Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2022, 21, 95-104.	0.1	2
36	The role of thrombophilia genes in the clinical implementation of arterial and venous thrombosis in newborns. <i>BIO Web of Conferences</i> , 2020, 22, 02021.	0.1	1

#	ARTICLE	IF	CITATIONS
37	Association of Gene Variants of Plasmin (<i>FGB</i> -455 G>A (rs1800790), <i>F2</i> 20210 G>A) Tj EtQq1 1 0.784314 rGb1 /Overlock Thrombocytic (<i>ITGA2</i> 807 C>T (rs1126643), <i>ITGB3</i> 1565 T>C (rs5918)), Fibrinolytic (<i>PAI-1</i>) Tj EtQq1 1 0.784314 rGb1 /Overlock Case-Controlled Study. <i>Pediatr. Áskia. Át Farmakologj. Át</i>, 2020, 17, 437-444.		
38	Suppressed miR-128-3p combined with TERT overexpression predicts dismal outcomes for neuroblastoma. <i>Cancer Biomarkers</i> , 2022, , 1-11.	0.8	1
39	4122 POSTER Application of NKX2, STEAP1 and CCND1 Genes Expression for Bone Marrow Involvement Detection in Patients With Ewing Family Tumours. <i>European Journal of Cancer</i> , 2011, 47, S290.	1.3	0
40	1400 Prognostic significant copy number variations (CNVs) defined by MLPA in primary and relapsed neuroblastomas (NB). <i>European Journal of Cancer</i> , 2015, 51, S197-S198.	1.3	0
41	Integrative analysis of bone marrow disease in neuroblastoma patients by DNA, RNA and protein markers. <i>European Journal of Cancer</i> , 2017, 72, S143.	1.3	0
42	Unusual Immunophenotypes in the Bone Marrow of Infants with Acute Leukemia: Minimal Residual Disease or ATRA-Mediated Regeneration?.. <i>Blood</i> , 2007, 110, 4260-4260.	0.6	0
43	Qualitative and Quantitative Concordance of Minimal Residual Disease Data Assessed by Multicolor Flow Cytometry and PCR of Fusion Gene Transcripts In Childhood B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 1720-1720.	0.6	0
44	Minimal Residual Disease Monitoring by Quantification of Fusion Gene Transcripts In Infant with MLL-rearranged Acute Lymphoblastic Leukemia Treated by MLL-Baby Protocol. <i>Blood</i> , 2010, 116, 2731-2731.	0.6	0
45	Flow Cytometric Leukemic Blasts Detection in Cerebrospinal Fluid of Children with Acute Leukemias. <i>Blood</i> , 2011, 118, 1449-1449.	0.6	0
46	Molecular Genetic Characterization of 3'-Deletion of MLL Gene in Infant Acute Leukemia.. <i>Blood</i> , 2012, 120, 2498-2498.	0.6	0
47	Identification Of Low Risk Group In Infants With Acute Lymphoblastic Leukemia By Flow Cytometric Minimal Residual Disease Measurement At Day 15 Of Interfant-99 and Interfant-06 Protocols Treatment. <i>Blood</i> , 2013, 122, 1333-1333.	0.6	0
48	Prognostic impact of copy number variations in neuroblastoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e21009-e21009.	0.8	0
49	Abstract 1900: Prognostic significance of genetic aberrations in neuroblastoma. , 2014, , .		0
50	Concordance and Prognostic Significance of Minimal Residual Disease Detection in Peripheral Blood and Bone Marrow Samples of Infants with MLL-rearranged Acute Lymphoblastic Leukemia Treated By MLL-Baby Protocol. <i>Blood</i> , 2014, 124, 2404-2404.	0.6	0
51	Abstract 1626: Evaluation of the expression of neuroblastoma-associated genes for bone marrow (BM) involvement and minimal residual disease (MRD) detection. , 2015, , .		0
52	Are non-cystic fibrosis bronchiectasis a result of primary antibody deficiency? , 2015, , .		0
53	Detection of Translocation t(7;12)(q36;p13) in Infants with Acute Myeloid Leukemia By Novel 3-Color Fluorescent in Situ Hybridization Approach. <i>Blood</i> , 2015, 126, 3827-3827.	0.6	0
54	Relapse Prediction By Flow Cytometric Minimal Residual Disease Assessment in Infants with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 1731-1731.	0.6	0

#	ARTICLE	IF	CITATIONS
55	ΔΥΔμΝΕΔμΝΝ,ΝΕΔ³⁴Δ¹ΔºΔ, Ν...ΝΕΔ³⁴Δ¹⁴Δ³⁴ΝΔ³⁴Δ¹⁴Δ¹⁴Δ³⁴Δ³⁴ ΝΕΔºΔ¹Δ³⁴Δ¹⁴Δº 11q23 Δ;ΝΕΔ, Δ³⁴ΝΝ,ΝΕΝ«Ν... Δ¹⁴Δ,ΔμΔ»		
56	Lack of micro-RNA 128A expression as a novel prognostic marker in neuroblastoma patients and combination with TERT hyperexpression to define patient outcomes.. Journal of Clinical Oncology, 2017, 35, e22014-e22014.	0.8	0
57	Rare cases of laboratory tests discrepancies in diagnostics of pediatric Burkitt lymphoma/leukemia. Oncogematologiya, 2018, 13, 76-82.	0.1	0
58	Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks. Blood, 2019, 134, 2747-2747.	0.6	0